Table 2.
Treatment protocols and indicators.
| Disease | Study ID (Author, year) | Treatment group | Contral group | Duration/follow measure | Outcome measure |
|---|---|---|---|---|---|
| Depressed | Duan et al., 2020 | FMT + BDD | FMT | 8 week/NR | HAMD, KMI, NE, 5-HT, TER, IAR |
| Meng and Zhang, 2020 | Fluoxetine + BDD | Fluoxetine | 8 week/NR | HAMD, SDSS, NIHSS, TER, IAR | |
| Zhang et al., 2019 | Paroxetine + BDD | Paroxetine | 8 week/NR | HAMD, NIHSS, QOL-100, TER, IAR | |
| Guo et al., 2016 | FMT + BDD | FMT | 6 week/NR | HAMD, PSQI, 5-HT, NE, TER, FSH, LH, LH, E2 | |
| Li and Gao, 2014 | Fluoxetine + BDD | Fluoxetine | 6 week/NR | HAMD, TER, STCM(AS, SD, Despair) | |
| Wang et al., 2014 | Vitamins + Ginkgo + BDD | Vitamins + Ginkgo | 4 week/NR | HADS, TER | |
| Miu et al., 2012 | GJS + BDD | FMT | 6 week/NR | HAMD, TER | |
| Tang and Bu, 2012 | Fluoxetine + BDD + GJS | Fluoxetine | 2 week/6 m | NIHSS, OHS, ADL, PSD | |
| Nie et al., 2010 | BDD | Paroxetine | 8 week/NR | HAMD, TER, IAR | |
| Chen et al., 2004 | BDD | Paroxetine | 4 week/NR | ADL, HAMD, NDS | |
| Yin et al., 2014 | GJS + BDD | FMT | 6 week/NR | HAMD, TER | |
| Wang et al., 2015 | GJS + BDD | Duloxetine | 8 week/NR | HAMD, KMI, TER, IAR | |
| Wen et al., 2018 | GJS + BDD | Fluoxetine | 6 week/NR | HAMD, TER | |
|
| |||||
| Menopausal syndrome | Xie et al., 2020 | GJS + BDD | Oryzanol | 4 w/NR | KMI, TER |
| Shen et al., 2019 | EV + BDD | EV | 3 m/NR | CD-(3, 4, 8), IL-2, TER, QL | |
| Song et al., 2018 | Metformin + FMT + BDD | Metformin + FMT | 60 d/NR | HAMD, HAMA, TER, C-, 348 | |
| Zhou et al., 2015 | Nilestriol + BDD | Nilestriol | 4 w/NR | CD-(3, 4, 8), IL-2, TER, LH, FSH, E2, T, PRL | |
| Zhang et al., 2012 | Paroxetine + BDD | Paroxetine | 4 w/NR | TER | |
| Han and Wan, 2020 | Estradiol + BDD + HES | Estradiol | 3 m/NR | KMI, MENQOL(BC, psychological, body, sex), SAS, SDS, PSQI, E2, FSH, LH, NE, 5-HT, NO, ET-1, CGRP, TER, YDFPS | |
|
| |||||
| Insomnia | Guo et al., 2019 | SS + BDD | SS | 2 w/NR | TER |
| Zhao and Yuan, 2019 | Paroxetine + BDD | Paroxetine | 3 w/NR | NIHSS, TER, SQ | |
| Xin et al., 2018 | BDD | Zopiclone | 2 w/NR | PSQI | |
| Zhang et al., 2018 | BDD + BEP | Estazolam | 4 w/NR | TER, FAT, ST, SD, NNW | |
| Zhang et al., 2015 | BDD + YJW | Estazolam | 4 w/NR | TER | |
| Pan et al., 2015 | Bupleurum + KOS + BDD | ZZ | 2 w/1 m | AIS-8, TER | |
| Wang et al., 2015 | Acupuncture + BDD | Diazepam + Diethylstilbestrol | 3 w/NR | TER, IAR | |
| Li et al., 2014 | SS + BDD | NR | 2 w/NR | TER | |
| Guan et al., 2020 | Trazodone + BDD | Trazodone | 3 m/1m | HAMD, PSQI, ASRSA, TER | |
| Li et al., 2019 | BDD + EA | Zopiclone | 28 d/NR | PSQI, HAMA, GSP, IAR, TSS | |
| Zhang et al., 2019 | BDD | Alprazolam | 30 d/NR | PSQI, TER, TSS | |
| Qu and Sun, 2019 | BDD + SS | Estazolam | 2 w/NR | TER, IAR | |
| Wang et al., 2008 | BDD | Alprazolam | 12 w/NR | PSQI, TER, AR, FAT, ST, SE, DN, Drowsiness | |
Note. HAMD, hamilton depression scale; KMI, kupperman; NE, norepinephrine; TER, total effective rate; IAR, incidence of adverse reactions; SDSS, social dysfunction scale; NIHSS, national institutes of health stroke scale; QOL-100, quality of life-100; PSQI, pittsburgh sleep quality index; FSH, follicle stimulating hormone; LH, luteinizing hormone; E2, estradiol; STCM, symptoms of traditional Chinese medicine; AS, anxiety somatization; SD, sleep disorder; HADS, hospital anxiety and depression scaleor; OHS, social function evaluation; ADL, activity of daily living; PSD, post-stroke depression; NDS, neurological deficit score; T lymphocyte CD subgroup, CD-(3, 4, 8); QL, quality of life; HAMA, hamilton anxiety scale; T, testosterone; PRL, prolactin; MENQOL, menopause-specific quality of life questionnaire; BC, blood; circulation; SAS, simpson-angus scale; SDS, anxiety self-rating scale; NO, nitric oxide; ET-1, endothelin-1; CGRP, calcitonin gene-related peptide; YDFPS, yin deficiency and fire prosperity syndrome; SQ, sleep quality; FAT, falling asleep time; ST, sleeping time; SD, sleep depth; NNW, number of night wakes; AIS-8, athens insomnia scale; ASRSA, asberg side-effect rating scale for antidepressant; GSP, glycosylated serum protein; TSS, TCM symptom score; SE, sleep efficiency; DN, dreaminess or nightmares, LE, lack of energy; FMT, flupenthixol and meritroxine; BDD, baihe dihuang decoction; GJS, ganmai jujube soup; EV, estradiol valerate; HES, huanglian ejiao soup; SS, suanzaoren soup; zopiclone; BEP, beans in ear points; YJW, yueju wan; KOS, keel oyster soup; EA, ear acupuncture; ZZ, zolpidem tartrate.